Trial site

North Texas Endocrine Center

Dallas, Texas 75231, United StatesNot linked to an institution yet

12running trials
15closed trials

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions: Type 2 diabetes14 trials
Obesity11 trials
Type 1 diabetes7 trials
Coronary artery disease3 trials
Stroke3 trials
Chronic kidney disease2 trials
High blood pressure2 trials
Familial hypercholesterolaemia1 trial
Heart failure1 trial
Peripheral artery disease1 trial
Phase: Phase 324 trials
Phase 23 trials
Status: Completed15 trials
Active, not recruiting7 trials
Recruiting4 trials
Not yet recruiting1 trial
Lead sponsor: Novo Nordisk A/S14 trials
Eli Lilly and Company7 trials
Novartis Pharmaceuticals3 trials
Boehringer Ingelheim1 trial
Inversago Pharma Inc.1 trial
and 1 more

Running trials

Not yet recruiting
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
NCT07720271· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Active, not recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
NCT07503210· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199· Phase 3· Novo Nordisk A/S· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
NCT05762107· Phase 2· Zucara Therapeutics Inc.· Source
Contact: Michelle Katz
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

High blood pressure2 recruiting
Obesity2 recruiting
Type 2 diabetes2 recruiting
Type 1 diabetes1 recruiting

Closed trials

Completed
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
NCT06584916· Phase 3· Eli Lilly and Company· Source
Completed
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
NCT06326060· Phase 2· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
NCT06269107· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06221969· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540· Phase 3· Novo Nordisk A/S· Source
Completed
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
NCT05822830· Phase 3· Eli Lilly and Company· Source
Completed
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
NCT05394519· Phase 3· Novo Nordisk A/S· Source
Completed
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
NCT05514548· Phase 2· Inversago Pharma Inc.· Source
Completed
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
NCT05463744· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
NCT05462756· Phase 3· Eli Lilly and Company· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
NCT05352815· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
NCT05259033· Phase 3· Novo Nordisk A/S· Source
Completed
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· Phase 3· Eli Lilly and Company· Source
Completed
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
NCT04023552· Phase 3· Novartis Pharmaceuticals· Source
Completed
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
NCT04184622· Phase 3· Eli Lilly and Company· Source

Site data: ClinicalTrials.govUpdated 14 Nov 2026

Report an error